Profusa, Inc. (PFSA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74319X2071
Profusa, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -27.71 m USD |
| EBIT | -33.30 m USD |
| Net income | -35.82 m USD |
| Diluted EPS – continuing operations | -107.01 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Profusa, Inc.
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
More stocks
- ScanTech AI Systems Inc. (STAI)
- LIPELLA PHARMACEUTICALS INC. (LIPO)
- Sleep Number Corp (SNBRQ)
- ADVENT TECHNOLOGIES HOLDINGS, INC. (ADNH)
- Banzai International, Inc. (PARA)
- Smart Powerr Corp. (CREG)
- PHOENIX MOTOR INC. (PEVM)
- HIGH WIRE NETWORKS, INC. (HWNI)
- ALLURION TECHNOLOGIES, INC. (ALUR)
- Vivakor, Inc. (VIVK)
- STARGUIDE GROUP, INC. (STRG)
- Tenon Medical, Inc. (TNON)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.